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Abstract
Despite over a century of clinical use and a well-documented record of efficacy and safety, a growing minority in
society questions the validity of vaccination and fear that this common public health intervention is the root-cause
of severe health problems. This article questions whether growing public anti-vaccine sentiments might have the
potential to spill-over into other therapies distinct from vaccination, namely allergen-immunotherapy. Allergen-
immunotherapy shares certain medical vernacular with vaccination (e.g., allergy shots, allergy vaccines), and thus
may become “guilty by association” due to these similarities. Indeed, this article demonstrates that anti-vaccine
websites have begun unduly discrediting this allergy treatment regimen. Following an explanation of the anti-vac-
cine movement, the article aims to provide guidance on how clinicians can respond to patient fears towards aller-
gen-immunotherapy in the clinical setting. This guide focuses on the provision of reliable information to patients
in order to dispel misconceived associations between vaccination and allergen-immunotherapy, and the discussion
of the risks and benefits of both therapies in order to assist patients in making autonomous decisions about their
choice of allergy treatment.
Review
Vaccination is the medical sacrament corresponding to
baptism. Whether it is or is not more efficacious, I do
not know.
Samuel Butler (1835-1902)
In 2009, the National Film Board of Canada and Play
Films released the documentary film, Shots in the Dark
[1], which showed interviews of parents of children that
experienced severe cognitive and physical decline follow-
ing immunization (better known as ‘vaccination’
amongst the lay-public and anti-vaccine proponents [2]).
While the correlation between these harms and vaccina-
tion are purely anecdotal, the parents depicted in this
documentary adamantly believe, due to their personal
experience, that vaccines cause debilitating illness. Simi-
lar sentiments abound on the social networking website,
Facebook®, where several hundred anti-vaccine fan-
groups and discussion forums, with membership in the
thousands, aim to inform the public of the dangers asso-
ciated with this common public health intervention
(search was performed by this author during December
2009, using the search term ‘vaccination’ with the Face-
book search engine). In addition to social networks,
internet searches using the term ‘vaccination’ with pop-
ular search engines now yield a majority of links to anti-
vaccine websites [3]. These are but a few examples
demonstrating a growing and highly visible anti-vaccine
movement around the world [4], where the extreme and
often unfounded fears and emotive discourse currently
invoked in public debates concerning the safety of vac-
cines resemble mass-hysteria.
The consequence of growing resistance towards vacci-
nation is the increase in morbidity and mortality from
the resurgence of once uncommon infections, specific
examples being recent epidemics of pertussis [5] and
measles [6,7] in the developed world. This alone poses a
formidable challenge to public health. It also worth
questioning, however, whether challenges stemming
from vaccine hysteria might be greater than initially
thought: Can vaccine hysteria compromise health inter-
ventions other than vaccination initiatives? This article
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any medium, provided the original work is properly cited.raises such a possibility by describing how the anti-vac-
cine movement may unexpectedly tarnish public percep-
tions towards allergen-immunotherapy, a treatment
regimen for allergy which employs therapeutics that are
similar to, yet distinct from, vaccines. Indeed, this article
will demonstrate that propagandist anti-vaccination
websites have started transposing vaccine-fears onto
allergenic extracts and recommend that the public
should refuse allergen-immunotherapy. Subsequent to
descriptions of the similarities and differences between
these therapeutic interventions, an overview of the anti-
vaccine movement will provide a basis for an informa-
tional guide aimed at countering patient resistance to
allergen-immunotherapy originating from the anti-vac-
cine movement.
Since the foundations of the anti-vaccine movement
stem primarily from unfounded fears [4], many experts,
but not all [8], recommend that health officials should
focus on providing patients with reliable and truthful
information about the risks and benefits of vaccination
in order to counter current misconceptions [9,10]. The
policy proposals herein concur with these recommenda-
tions, but are framed within the context of allergen-
immunotherapy. Overall, this article aims to provide an
informational guide for allergy specialists that can aid
them in attending to patients’ concerns about allergy
treatment regimens that originate from vaccination-
related fears, should clinicians encounter a vaccine-
anxious patient in the clinical setting.
But first, the discussion will centre on identifying key
similarities and differences between vaccination and
allergen-immunotherapy.
Vaccination and allergen-immunotherapy: When
‘apples’ seem like ‘oranges’
Vaccination
From the perspective of population health, the benefits
accrued by humanity from the development and effec-
tive deployment of vaccination initiatives is immense
and undeniable. One particularly reputable achievement
has been the eradication of smallpox from the global
population during the 1970’s [11]. A multitude of once
common vaccine-preventable diseases are following a
similar path of diminution, such as measles, rubella and
polio, which are now uncommon in the developed
world [12,13] and increasingly less common in the
developing world [14]. With a clinical history that dates
over a century, a high vaccination rate of infants in the
industrialized world, and an availability of annual vac-
cines against influenza, immunization efforts are by far
the most well recognized public health intervention.
However, vaccination initiatives have also been met with
various degrees of public opposition throughout history,
which will be described further below.
Vaccination–also described as ‘shots’, immunization,
or inoculation–is a primary-level intervention that
aims to prevent the initial emergence of disease. Pre-
venting the transmission of infectious disease in this
context resides in the controlled exposure of inacti-
vated or weakened forms of infectious agents to the
immune system, which in turn induces resistance
(immunity). Early forms of vaccination involved inva-
sive procedures that carried a significant risk for infec-
tion and produced permanent scars–the insertion of
calf thymus particles into skin abrasions as a means
for smallpox inoculation is but one example [15]. Cur-
rent vaccination methods are benign in comparison,
being typically administered by small injections. And
certain inoculations are painless since they involve the
ingestion of oral vaccines [16,17]. Since vaccines are
solutions of labile biological material, they commonly
contain preservative agents in order to retain their effi-
cacy over time [18]. Other common vaccine additives
are adjuvants, which are typically in the form of alumi-
nium salts [19]. Adjuvants increase the reactivity
(immunogenicity) of the vaccine by delaying the
absorption of the active ingredients into the body, thus
allowing for a prolonged interaction between the vac-
cine and the immune system. Therefore, adjuvanted
vaccines typically require fewer injections (i.e., ‘booster
shots’) in order to induce long-term immunity.
Allergen-immunotherapy
Allergic sensitivities affect roughly 25% of the popula-
tion of the developed world and cause numerous mor-
bidities including hay-fever, skin rash, digestive
disturbances, and allergy-induced asthma [20-23]. A
variety of treatment strategies for allergy exist, which
include pharmacotherapy, allergen avoidance and elimi-
nation, and allergen-immunotherapy (IT).
Similar to vaccination, IT has a lengthy clinical history
that goes back nearly a century [24]. The therapy uti-
lizes a class of therapeutics known as allergenic extracts,
which are commonly referred to as ‘allergy vaccines’ or
‘allergy shots’ [25], pseudonyms that resemble terms
often associated with therapeutics for vaccination.
Indeed, allergenic extracts have a significant resem-
blance to vaccines and are administered by equivalent
methods, primarily via injection but also increasingly by
oral routes [26]. Furthermore, like vaccines, allergenic
extracts often contain preservatives and adjuvants in
order to increase their stability and therapeutic efficacy
[27,28]. Yet, unlike injected vaccines, which are most
often injected into muscle tissue or intra-dermally, aller-
gen vaccines are administered subcutaneously. As their
name implies, allergenic extracts are made by the
extraction of allergens from biological sources (e.g., che-
mical extraction of cat allergens from cat hair clippings).
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increasing doses of allergens over the course of months
and sometimes years. After multiple injections, physiolo-
gical aspects of the immune system become altered and
allergy-related IgE antibody levels are brought into bal-
ance with immune mediators that do not induce allergic
responses and related histamine release (for a concise
review, see: [29]). In other words, the therapeutic goal of
IT is to induce an immune ‘switch’ or ‘modification’
away from allergic reactions as a means to induce toler-
ance. Therefore, in contrast to primary-level vaccination,
IT is a tertiary-level health intervention, meaning that
its goals are to diminish morbidities and negative health
consequences of an illness already prevalent amongst
the population. Relative to other allergy treatment stra-
tegies (e.g., pharmacotherapy, avoidance), IT has notable
advantages. Of most significance is the fact that IT is
the only treatment that can induce life long tolerance to
(sometimes cure) allergic sensitivities, and thus can sig-
nificantly reduce the need for consistent administration
of costly drugs [30,31].
To this point, this author has focused on identifying
key similarities and differences between vaccines and IT
therapeutics (summarized in Table 1; note that the term
“Allergen mixture” stated in the table refers to the biolo-
gical components extracted from the biological source,
which in turn contains both major and minor allergens–
not to be confused with Mixed-versus Single-IT
regimens). Many of these similarities could be readily
identified by the lay-public, especially in terms of the
names and administration routes used for both classes
of therapeutics. However, IT and vaccination are radi-
cally different, especially in terms of the clinical/
biomedical details of both therapies and the active
ingredients used as therapeutics. It is unlikely that popu-
lation groups other than clinicians and health officials
would be fully cognizant of these important details. This
then raises the reasonable possibility that the growing
wave of public resentment and fear towards vaccination
could ‘spill-over’ and influence public perceptions
towards allergy treatments. A subsequent section of this
article will demonstrate that the ‘spill-over effect’ has
indeed begun. To conclude, vaccination is a proverbial
‘apple’ and IT is an ‘orange’. While both share similari-
ties in being ‘fruits’, they remain fundamentally different
within a clinical context. Their similarities are, however,
significant within a population context. Indeed, it is
understandable that members of the lay-public are not
adequately familiar with either therapy to be able to dis-
tinguish, say, ‘vaccines’ from ‘allergen vaccines’.I nt h e
eyes of the public, apples likely appear equivalent to
oranges and thus challenges originating from vaccine
fears may well extend beyond that of vaccination.
Side-effects from vaccination and immunotherapy:
known, correlated, and unsubstantiated
As is the case for all categories of therapeutics, vaccines
do occasionally cause side-effects and adverse drug reac-
tions (ADRs) [32]. Most reactions are of little concern
and remain localized at the injection site, such as pain,
inflammation, and oedema. Within a minority of
patients, certain vaccine recipients experience an allergic
reaction that is often not due to the vaccine’s active
ingredients but rather its packaging, additives, or trace
contaminants originating from the manufacturing pro-
cess [18] (though for a minority of vaccines, the active
Table 1 Similarities and differences between vaccination and allergen-immunotherapy
Vaccination Allergen-Immunotherapy
Similarities Clinical history Over a century Nearly a century
Therapeutics contains adjuvants and preservatives? Yes, often Yes, often
Synonyms: Medical and lay-public vernacular a) shots a) allergy shots
b) vaccines b)allergen vaccines
c) IMMUNization c) IMMUNotherapy
Administration Injection, occasional oral Injection, occasional oral
Physiological target Immune system Immune system
Differences Category of prevention Primary Tertiary
Active ingredient Derivatives of infectious agent Allergen mixture
Physiological response Induce immune response Alter/modify immune response
Length of treatment Short, sometimes months Lengthy, months to years
Number of injections Often single; may require ‘boosters’ Multiple injections
Tissue injected Intra-muscular Subcutaneous
Risk of anaphylaxis Extremely low Low, but significant
Treatment goal Resistance/immunity to infection Tolerance to allergen
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reaction, as is the case with tetanus and diphtheria tox-
oids [33]). For example, production of most influenza
vaccines involves propagation of the virus within
chicken eggs; some individuals have allergic sensitivities
towards eggs and thus may develop a reaction to trace
amounts of egg protein within the administered vaccine.
Severe allergic reactions to vaccines do occur and can
result in an anaphylactic reaction. Fortunately, anaphy-
lactic and other severe reactions to vaccines occur at a
rate of less than 1 per million administered doses [18],
which signifies that mortality from vaccination is
exceedingly rare [34]. To expand, estimates concerning
the American population indicate that approximately
180 deaths from vaccination occur each year, which is
roughly equivalent to the number traffic accident fatal-
ities that occur every 1.5 days [35]. In addition to aller-
gic reactions, possible vaccine contaminants have been
correlated with a sudden rise in the incidence of a neu-
rological condition known as Guillian-Barré syndrome
(GBS) in America following the 1976 influenza vaccina-
tion campaign [36]. Subsequent flu vaccination cam-
paigns have not been correlated with the syndrome
[37,38]; thus, whether or not GBS is an ADR risk of vac-
cination remains debatable [39,40]. A final well-known–
and ironic–vaccination risk concerns the possibility to
transmit infectious disease from vaccines containing live
active ingredients [18]. However, infections originating
from live vaccines primarily occur in immuno-compro-
mised and immuno-suppressed patients and thus, ‘live’
vaccines are contraindicated for this minority of the
population.
Overall, the risks for serious ADRs to vaccines are
arguably acceptable in terms of the population-level
benefits that vaccination offers in preventing serious
morbidity and mortality from infections, as well as pro-
viding the ability to “expand opportunities for health
care by sparing ... resources that would otherwise be
needed to care for individuals with preventable infec-
tious diseases” [41] [p.487]. More importantly, relative
to vaccines, rates of serious ADRs (e.g., death) are signif-
icantly higher for many widely prescribed medications
[42] such as statins [43], blood thinners [44], antidepres-
sants [45], but are routinely employed in clinical prac-
tice despite these known risks. To conclude, the
relatively low risks of complications associated with vac-
cination are arguably acceptable and should not discou-
rage their use in the general population.
Additional pathologies pertaining to severe cognitive
and physical disability have been observed to coincide
temporally with the administration of vaccines. How-
ever, the suggested correlations between these medical
anomalies and vaccination are unsubstantiated and, at
best, purely anecdotal [18,46,47]. One notable, but
thoroughly debunked, example pertains to autism in
children, where the mercury-containing vaccine preser-
vative, thimerosal, was one of many [46] purported vac-
cine-related risk factors in the development of this
disorder. Others have suggested that the multitude of
vaccines used in childhood immunization programs are
too numerous and thus might ‘overload’ a child’s devel-
oping immune system. One suggested result of this
overload might be an increased risk for immune disor-
ders such as allergy and allergy-induced asthma. Addi-
tional examples include correlations with diabetes,
multiple sclerosis, and sudden infant death syndrome.
The tentative associations between vaccination and
these pathologies have since undergone extensive eva-
luation through a variety of methods at independent
research institutes. The results from these studies dis-
credit the association of these illnesses with vaccination
[18,46-48]. It is also important to note that amidst
much media frenzy, the initial research article that sug-
gested a link between vaccination and autism was
retracted from The Lancet for numerous reasons ran-
ging from unethical research practices, conflicts of inter-
est undeclared by the authors, and questionable
scientific methodology [49-51]. (Note that the lead
author at the centre of this controversy, Dr. Wakefield,
recently lost his license to practice medicine in the Uni-
ted Kingdom [52]).
There are several notable ADRs associated with aller-
gen vaccines used in IT as well. The majority of adverse
reactions observed are similar to those described pre-
v i o u s l yf o rv a c c i n e s ,b e i n gp a i n ,i n f l a m m a t i o n ,a n d
oedema localized at the site of injection [53]. However,
during the initial phase of therapy these reactions are
often in greater magnitude than those observed with
regular vaccines, which is understandable since IT func-
tions through the injection of allergenic therapeutics
into an allergen-sensitized patient. For adults, these
localized adverse reactions are simply unpleasant, yet
can be a cause for significant psychological stress when
experienced by children [54]. It is important to note
that allergic reactions to IT therapeutics are: 1)
expected, 2) originate from the active ingredients of the
therapeutic, 3) and are an unavoidable aspect of the
therapy. This is in sharp contrast to allergic reactions to
vaccines, which are unexpected, uncommon, and pri-
marily due to additives or trace contaminants in the
final therapeutic. As is the case with vaccines, life-threa-
tening allergic reactions such as anaphylaxis can occur
during the course of IT. However, since IT necessitates
multiple injections of an allergenic compound, the inci-
dence of anaphylactic reactions is far greater than that
observed with vaccines, i.e., estimated to range between
6 events for every 100 injections [55] to 6 events for
every 1000 injections [56]. These risks are well known,
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follow strict practice guidelines that minimize adverse
reactions to IT [29,57,58]. When administered safely,
deaths from IT are extremely rare. Unlike vaccines,
there are no reports of severe cognitive or physical dis-
abilities associated with the administration of IT thera-
peutics. However, two case reports representing two
patients, one for scleroderma [59], the other for Sjög-
ren’s syndrome [60], associated temporally the onset of
these diseases with IT, though exact causation was not
established.
Building from the previous description of the risks of
ADRs with vaccination, the discussion will now focus
on the growing public sentiments against vaccination.
The foundations of the anti-vaccine movement
Waves of public resentment and fears centering on vac-
cination are not a modern phenomenon, but rather one
that has reappeared throughout the history of this inter-
vention [61]. Unlike the earlier vaccination efforts
against smallpox during the 1800’s, where anti-vaccine
propaganda was disseminated via posters and newspa-
pers, proponents against vaccination now have numer-
ous additional means to communicate their positions to
the general public, the Internet being of particular
importance [3,4,62,63]. It is important to note that the
growing plethora of anti-vaccine websites exist at a time
where millions of people are using the Internet as a
means to obtain medical information [64].
Studies that analyzed the content of anti-vaccine web-
sites indicate that anti-vaccine proponents vocalize a
m i n o r i t yo fj u s t i f i a b l ec r i t i c i s m sa l o n g s i d eam a j o r i t yo f
manipulative information [3,4,8,62,63]. For example,
many criticisms stem from ethical issues in relation to
imposed vaccination and the loss of civil liberties, as
well as avoiding unnecessary vaccine-risks in the
absence of infection. Indeed, coercive vaccination poli-
cies do exist, such as restrictions in school enrolment
for unvaccinated children [65], and many people view
these policies as unethical. However, vaccine opponents
equate most vaccination programs with severe forms of
government oppression and often omit the fact that
most vaccination programs involve voluntary compli-
ance; only rarely is vaccination obligatory. Moreover,
purported claims that vaccines are currently unnecessary
are uncorroborated. Indeed, certain vaccine-preventable
diseases are not overtly prevalent, but this does not
mean that they no longer exist within society. Vaccine
opponents also commonly note undisputed vaccine-
ADRs, including allergic reactions, infections, and death.
However, these anti-vaccine websites grossly exaggerate
the incidence of such rare ADRs.
Propagandist information is another commonality
shared by anti-vaccine websites [3,4,8,62,63]. While
discredited by reliable scientific evidence, vaccine-oppo-
nents remain adamant that inoculation is the cause of
debilitating diseases such as autism and multiple sclero-
sis. Others still claim that multiple vaccines can ‘over-
load’ the immune system and is the cause of allergy, and
in general, vaccination is ‘fundamentally unnatural’.
Many sites report very emotional stories of vibrant,
healthy children that succumbed to horrific illnesses or
death following the administration of common child-
hood vaccines, but they do not demonstrate a causative
link between the two events. Finally, many make claims
that vaccination efforts are fraught with controversy and
describe elaborate conspiracy theories that explain the
‘true’ motives underlying vaccination policies. Popular
conspiracy theories include: assertions that vaccines are
ineffective and that infections began to disappear prior
to vaccination; governments and scientists are hiding
evidence of the actual harms caused by vaccines; vaccine
efforts are schemes to generate profits for large pharma-
ceutical companies; and that vaccine initiatives are
means to conduct genocide.
It is unknown to what extent anti-vaccine propaganda
disseminated through media outlets or the Internet is
undermining public trust in vaccination. Numerous sur-
v e y ss u g g e s tt h a ti ti ss i g n i f i c a n t .A tam i n i m u m ,a n t i -
vaccination websites are observed to influence public
perceptions towards vaccination, where parents whom
exempt their children from receiving common vaccines
often have obtained information from such Internet
sources [66]. Furthermore, one study [67] demonstrated
that up to half of American survey respondents refused
the annual influenza vaccine due to the belief that they
would develop influenza disease from the vaccine.
Another American study [68] found that 15% of parents
of young children did not want their child to receive
any of the recommended childhood inoculations. More-
over, it is incorrect to assume that anti-vaccine senti-
ment is isolated amongst uneducated people or certain
minority groups that share radical ideologies. Rather, a
significant proportion of American supporters of the
current anti-vaccination movement are of members of
the middle class and have some level of university edu-
cation [69]. By and large, these studies suggest that anti-
vaccine sentiment exists throughout society, where the
unfounded fears and anxiety now associated with vacci-
nation could constitute a form of mass-hysteria. When
taken as a whole, the arguably irrational nature of vac-
cine hysteria should raise concerns about whether other
‘vaccine-like’ medical interventions may also become
tarnished in the public eye, as is argued here concerning
IT. Indeed, information found by this author on the
Internet indicates that public vaccine-fears and vaccine-
opposition have started being transposed onto IT and
allergy therapeutic regimens.
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and Wolfe and colleagues [2,63], and using search terms
such as “anti-vaccination, vaccine, allergy, immunother-
apy” in March 2010, yielded anti-vaccine websites and
Internet blogs that have begun discussions questioning
the safety and utility of IT. (A detailed quantification of
these websites is beyond the scope of this article, but
would be an interesting topic for future investigations).
Many sites also confuse vaccination ADRs with IT treat-
ments and purport manipulative and/or false informa-
tion concerning IT and allergies. One notable example
is blog entries [70] from the site, http://m.digitaljournal.
com. What appears to be a blog entry from a member
of the general public whose child received IT demon-
strates that vaccine ADRs and related fears are being
mistakenly associated with allergenic extracts–this entry
relates to bacterial contamination of vaccines and the
possible link with Guillain-Barré Syndrome (GBS):
“... after reading this report and reading there might
have been bacterial contaminant in the H1N1 vac-
cine makes me wonder if there could have been bac-
terial contaminant in the allergy shots.”
A subsequent entry on the same blog employs scienti-
fic jargon and claims that allergenic extracts contain the
notorious “autism-causing” preservative, thimerosal:
“... if your son received an allergy shot from a multi
dose vial, he(sic) more than likely had thimerosal in
it. By weight thimerosal is 40.7% mercury. Mercury is
an e u r o t o x i na n dc a na f f e c tm a n ya r e a so fy o u r
body.”
Another blog entry [71] from the website, http://child-
healthsafety.wordpress.com, demonstrates similar convo-
luted and mistaken associations between vaccines and
allergenic extracts (skin prick tests are clinical assays
using allergenic extracts [e.g., peanut extract] in order to
diagnose allergen sensitivities [e.g., peanut allergy]; the
underline emphasis was added by this author):
“Vaccines are the direct cause of the food allergy epi-
demic. Why are the manufacturers of vaccines
allowed trade secret protection for vaccine ingredi-
ents? Why is peanut oil considered safe to inject
along with aluminum based on studies where chil-
dren eat the oil or based on the skin prick test? IT
ISN’T THE SAME!! The fatal food allergies are
directly caused by vaccines!! The evidence is there.”
Certain websites of supposed specialists in comple-
mentary and alternative medicine encourage patients to
reject IT in favour of treatments such as homeopathy
and often purport mistaken facts about IT and vaccina-
tion. Entries [72] within the website, http://e-holisti-
chealth.blogspot.com, are exemplary (underline
emphasis added):
(This entry compares allergenic extracts to vaccines)
“Allergy shots are often called “vaccines” because (1)
they are injected and (2) the intention of both is to
confer immunity.”
“... allergy shots must stop after 3 to 5 years and at
that time the doctor has to decide whether to con-
tinue them or not. That would suggest that the
cumulative effect of getting allergy shots compromises
immune function in some way or has other side
effects.”
“Both allergy shots and vaccines have risks for aller-
gic reactions, including anaphylaxis. The risk is
higher and more common with vaccines (for obvious
reasons).”
“...[IT] therapy only lessens the severity of the allergy
response and creates other side effects (headaches,
skin conditions, additional allergies).”
“Neither vaccination or allergy immunotherapy
addresses the underlying organ weaknesses and
immune system problems that make the person sus-
ceptible to infections and allergic reactions.”
As a final example, the popular and notorious anti-
vaccination website, Vaccination Liberation (http://www.
vaclib.org), warns the public to reject allergy-vaccines
and that the common aluminum salt adjuvants in aller-
genic extracts are of significant toxicological concern
[73] (for an analysis of the website, Vaccination Libera-
tion, see: [8]). Overall, this overview of Internet-based
information indicates that mistaken associations
between IT, vaccine-fears and the anti-vaccination
movement are a current reality.
Countering patient fears: a practical guide for
clinical allergists
The final section of this article will now outline an
informational guide to counter possible patient distrust
of IT originating from the anti-vaccine movement. Pol-
icy recommendations aimed at addressing public fears
towards vaccines have been proposed in the medical lit-
erature [9,10]. In brief, these recommendations empha-
size that patients are in need of reliable, understandable
and trustworthy information concerning immunization
in order to dispel common misconceptions associated
with the intervention. Such a strategy is also pertinent
in relation to anti-vaccine sentiments that unduly tar-
nish IT; information is key. Indeed, clinicians should be
prepared to suggest to patients where they can find reli-
able information on the Internet (for example, by
Behrmann Allergy, Asthma & Clinical Immunology 2010, 6:26
http://www.aacijournal.com/content/6/1/26
Page 6 of 11referring patients to the websites of the Canadian
Society of Allergy and Clinical Immunology [74], or the
American Academy of Allergy, Asthma and Immunol-
ogy [75]). Yet, while the Internet is a widely used public
source of medical information, it is invariably the start-
ing point for - and not a replacement of - seeking advice
from a trusted health professional.
Clinicians providing IT should be informed of the
effect vaccine fears may have on their clinical practice.
For one, clinicians specializing in allergy treatments may
be caught off-guard when encountering a patient that is
fearful of allergy therapeutics because of vaccine anxiety.
Clinicians may not be able to immediately understand
the underlying connections or reasons for these fears,
especially since an allergist knows that vaccination and
IT are fundamentally different therapies. Furthermore,
allergy specialists may not be adequately familiar with
the details of vaccination and the growing anti-vaccine
movement, which is understandable since vaccination is
typically not directly related to the treatment of allergic
sensitivities; more generally, it is the case that many
health care workers are unfamiliar with details concern-
ing vaccination and vaccine safety [4].
What information, then, is necessary and how should
it be conveyed to patients? The following section pro-
vides an informational guide for clinicians, structured in
the form of hypothetical questions vocalized in lay-pub-
lic language that address basic fears and misconceptions
concerning vaccination. Suggested methods to address
these questions are derived from the information pro-
vided in the previous sections of this article.
1) Shots, allergy shots: What’s the difference?
Clinical allergists will likely face a particular challenge in
communicating a simple explanation as to why immuni-
zation/vaccination/vaccines/shots are fundamentally
different from immunotherapy/allergy-vaccines/allergy-
shots. It is thus of utmost importance that allergy spe-
cialists are informed about the details of vaccination and
any associated fears. This should include familiarization
with common vaccine additives and adverse drug reac-
tions. Only then will clinicians have the trustworthy and
reliable information needed to provide a detailed com-
parison between each therapy, and so not be caught off-
guard by questions related to vaccine fears. Allergy spe-
cialists should be prepared to use their clinical knowl-
edge of IT to demonstrate the absolute differences
between vaccines and allergen vaccines. Recall that the
main differences between vaccination and IT are evident
within a clinical context that will unlikely be common
knowledge to members of the general public (see Table
1). Clinicians should thus focus on describing these
‘non-obvious’ clinical details in a readily understandable
manner. For example, patient-oriented discussions could
describe the difference between ‘allergen-tolerance’ ver-
sus ‘immunity’, and explain that allergen vaccines only
contain allergens; there is thus no risk of transmitting
infection with these drugs though this small risk does
exist with certain live vaccines. Of course, in an effort to
provide truthful and balanced information, clinicians
should not down-play any of the similarities between
vaccines and allergen-vaccines (e.g., both contain adju-
vants and preservatives), as well as not hesitate to state
that the risk of adverse reactions associated with IT is
greater than that of vaccination (though both have
excellent records of safety and efficacy, especially in
terms of vaccination).
2) Do allergy vaccines contain harmful additives?
This concern stems from real (e.g., allergic reaction to
additives) and unfounded (e.g., thimerosal, mercury, and
autism) risks related to vaccine ingredients. Clinicians
need to be informed of details of vaccine additives and
should be able to compare these with common additives
used in IT therapeutics. For example, allergy specialists
should be prepared to respond to basic questions con-
cerning thimerosal and mercury (e.g., vaccine manufac-
turers have voluntarily stopped using thimerosal in most
vaccine formulations [18,46]). Another example is that
clinicians should offer relevant comparisons such as:
allergen vaccines do not contain mercury metal but
often have harmless aluminium salts as adjuvants. Lastly,
clinicians should know if additive-free versions of allergy
vaccines are available in case a patient is adamantly
opposed to particular additives.
Of additional importance, clinicians should be able to
provide a basic level of information that will dispel com-
mon misconceptions linking vaccine additives and ser-
ious illness, as well as noting the true frequency at
which side effects, like allergic reactions, occur. How-
ever, vaccine-risks are not equivalent to allergen-vac-
cine-risks and this should be clearly explained. For
example, vaccine-related allergic reactions are unex-
pected, uncommon, and most often due to additives or
trace contaminants; IT-related allergic responses are
expected, caused by the active ingredients, are an una-
voidable aspect of the therapy, and treatments are medi-
cally supervised in order to minimize the risk of serious
harm.
3) Is this therapy unnecessary and a method for
pharmaceutical companies to make money?
This question represents one of many popular conspi-
racy theories purported by vaccine opponents. In gen-
eral, the efficacy and utility of vaccines are claimed to
be false and correspondingly, there are ulterior motives
underlying the administration of vaccines, which in this
case relates to profiteering. Thus, allergy specialists
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simply ‘laugh-off’ these irrational theories, but rather
counter them with rational arguments. In relation to the
above example, clinicians should note that IT aims to
induce long-term tolerance and can reduce the need for
consistent administration of costly allergy drugs that
only transiently reduce symptoms (for instance, a recent
study [31] demonstrated that immunotherapy-treated
patients had significantly lower 18-month median per-
patient total health care costs ($3,247 versus $4,872)).
This medical goal runs counter to efforts to generate
profits through consistent drug consumption. The same
argument applies to vaccination, being a cost-effective
means to reduce health care expenditures that would
otherwise be needed to treat infectious disease.
4) Will this treatment ‘overload’ my immune system?
Common criticisms of vaccination are that it is unna-
tural, and multiple vaccinations in particular are claimed
to produce immune dysfunction. The unfounded con-
cern that multiple vaccinations can ‘overload’ the
immune system is particularly pertinent to IT. Unlike
vaccination, which typically requires one or few injec-
tions, IT necessitates several injections over the course
of months or years. The appearance of overloading the
body with allergen-vaccines will likely seem even more
pronounced with this treatment relative to common
vaccination programs; this issue merits particular atten-
tion. Clinicians should thus be prepared for patient con-
cerns of ‘overloading the immune system’ and be able to
respond to such fears. One strategy to attend to this
concern is for a clinician to rehearse means to commu-
nicate with the patient as to why multiple injections are
needed as a means to induce tolerance. Certain IT treat-
ments require fewer injections, like rush-immunotherapy
[58], and clinicians should be prepared to recommend
these alternatives to patients fearing multiple injections
(if the therapy is available). Lastly, clinicians should be
prepared to respond to these concerns with rational
arguments, such as by informing the patient that our
immune systems are bombarded daily with numerous,
naturally occurring pathogens (moulds, bacteria,
viruses). These daily immune responses do not ‘over-
load’ one’s immune system, therefore why should the
occasional IT injection do so?
5) Will there be consequences if I refuse or stop
treatment (i.e., restrictions in school enrolment)?
This fear focuses on coercive or mandated vaccination
policies and a perceived attack on civil liberties. The
negative sentiments stemming from the perception of
being forced to undergo an unwanted medical interven-
tion is the source of much anti-vaccination rhetoric.
Clinicians need to be aware of how patients may
mistakenly think they are being forced or coerced into
treatment and be ready to assert that patients are free to
stop treatment whenever they choose. Clinicians should
inform patients that their treatment will remain confi-
dential and that third parties, such as government offi-
cials, will never know whether or not they received
treatment. It might also prove helpful to inform patients
fearful of coercion that their allergy poses no direct
harm to others, and thus, there is no need for third par-
ties to impose treatment under any circumstance.
6) Will I have an allergic reaction or develop additional
allergies from this treatment? Will I have a bad reaction
to the therapy? Can it kill me?
These questions exemplify how certain fears towards
vaccination can be partly justified as well as partly
unfounded, and share a common theme. Overall, anxi-
eties concerning adverse drug reactions, such as severe
allergic reactions and death, are partly do to the over-
statement of actual vaccination risks by anti-vaccine
proponents. Additionally, clinicians will likely be caught
off-guard by a patient’s assumption that an allergy treat-
ment might give them more allergies. Therefore, clini-
cians should be prepared to explain how these
assumptions stem from unfounded fears that vaccines
c a u s ei m m u n ed i s o r d e r sa n db ep r e p a r e dt oa s s e r tt h a t
a properly conducted IT regimen is a treatment that
will not result in additional allergies.
Fears of severe reactions and death stemming from
vaccination are particularly important in relation to IT
because the well-known and severe ADRs for both
therapies are roughly equivalent (e.g., mortality risks for
both therapies are primarily due to anaphylactic reac-
tions). Therefore, clinicians should be prepared to
explain that risk of death from anaphylaxis is indeed a
well-known concern, but is still very rare for both IT
and vaccination. Second, it is noteworthy that allergic
reactions in IT, unlike vaccination, are a recognized
(and planned for) unavoidable aspect of therapy and
these reactions are typically not severe; the patient
should be made aware of this fact. If the vaccine-anxious
patient cannot be convinced that minor risks of ADRs
with IT are arguably acceptable, the clinician should
support the patient in choosing alternate therapies (i.e.,
pharmacotherapy). Third, when encountering a vaccine-
anxious patient, clinicians should provide an at-length
discussion concerning the detailed practice protocols
that are followed in IT and that these protocols (e.g.,
supervision following therapy), strongly recommended
by the allergology community as imperative, are indeed
effective in significantly reducing the risk of serious
complications and death. (Regardless, this discussion is
necessary to enable the informed consent of the patient
in the first place.) It is important that clinicians are
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for IT than vaccination and to not hide this fact from
patients raising concerns towards vaccines. Overall, clin-
icians should know not to trivialize or omit discussion
of any risks with IT, no matter how minor, since vaccine
opponents have mislead many people into believing that
minor risks are major concerns; a counter to such mis-
information is access to objective information from a
trusted health professional.
Conclusions
The growing epidemic of allergic disease [76] is posing a
significant challenge for public health and indicates that
a multitude of treatment strategies for allergy will play
an increasingly important role in securing population
health. Allergen-immunotherapy will undoubtedly com-
prise a significant component in such efforts, yet pro-
moting this therapeutic intervention will face certain
challenges. For one, the time-consuming and inconveni-
ent nature of this therapeutic regimen already leads
many patients to abandon treatment prematurely [58].
In this article, it is suggested that additional challenges
originating from the growing anti-vaccination movement
might also encourage certain patients to oppose aller-
gen-immunotherapy as an appropriate treatment strat-
egy. A reasonable first step in countering this challenge
is to prepare allergy specialists for this possibility and
provide methods on how to respond to predictable
patient fears. Only if clinicians are knowledgeable in
vaccines and the anti-vaccination movement will they be
prepared to engage in dialogue with an anxious patient
and thus, dispel unreasonable associations assumed
between allergy treatments and vaccination. This article
provides information and guidance to aid clinicians in
this situation; however, the global community of allergy
specialists should now consider what additional
resources, information, and possible collaborations with
other health officials (e.g., public health practitioners),
will also prove helpful in promoting informed public-
perceptions of allergen-immunotherapy. The guidance
herein will hopefully serve as the initiator of this needed
discussion.
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